Capstone Therapeutics Corp. (CAPS) Company Profile - Business Overview, Management Team & Corporate Information - Stocknear

Capstone Therapeutics Cor...

NASDAQ: CAPS · Real-Time Price · USD
1.14
-0.02 (-1.72%)
At close: Sep 09, 2025, 10:40 AM

Company Description

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States.

It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism.

The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010.

Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Capstone Therapeutics Corp.
Capstone Therapeutics Corp. logo
Country United States
IPO Date Jan 28, 1993
Industry Biotechnology
Sector Healthcare
Employees 36
CEO Matthew E. Lipman

Contact Details

Address:
1275 West Washington Street
Tempe, Arizona
United States
Website https://www.capstonethx.com

Stock Details

Ticker Symbol CAPS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000887151
CUSIP Number 14068E208
ISIN Number US14068E2081
Employer ID 86-0585310
SIC Code 5030

Key Executives

Name Position
Matthew E. Lipman Chief Executive Officer, President, Secretary & Director
Edward C. Schultz Vice President of Finance, Chief Financial Officer & Treasurer

Latest SEC Filings

Date Type Title
Sep 04, 2025 DEF 14C Filing
Aug 25, 2025 PRE 14C Filing
Aug 18, 2025 8-K Current Report
Aug 15, 2025 424B3 Filing
Aug 15, 2025 8-K Current Report
Aug 15, 2025 10-Q Quarterly Report
Aug 15, 2025 NT 10-Q Filing
Aug 14, 2025 424B3 Filing
Aug 04, 2025 S-1 Filing
Aug 04, 2025 8-K Current Report